Clinical and Pathological Study on Effects of Qianggan Capsule Combined Lamivudine on Hepatic Fibrosis in Patients with Chronic Hepatitis B

ObjectiveTo study the therapeutic effects of Qianggan Capsule (QC) combined Lamivudine on hepatic fibrosis in patients with chronic hepatitis B. Methods Eighty-five patients were randomly divided into two groups, group A (40 cases) were treated with QC and Lamivudine and group B (45 cases) were treated with QC alone both for 6 months. Hepatic fibrosis related indexes and pathologic examination of liver biopsy were performed within 3 months before treatment and in 1 month after treatment. Results Serum levels of hyaluronic acid, collagen Ⅳ and laminin decreased markedly after treatment in both groups (P0.05). Hepatic histopathological examination showed that the total effective rate of impovement in activity of inflammation-necrosis and fibrosis was 80.0 and 70.0 in group A, 57.8 and 75.6 in group B, respectively, the combined treatment showed a better effect in improving the activity of inflammation-necrosis than QC alone (P0.05), but with no significant difference to the latter in improving fibrosis. Conclusion QC combined Lamivudine could markedly reduce the activity of hepatic inflammation-necrosis, QC alone could also improve hepatic fibrosis.